ESTRELLA IMMUNOPHARMA, INC. (ESLA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -9.68M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 6.98M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-9.68M | (m) | (m) | $6.98M | (m) | (m) |
| 2026-03-31 | $-13.25M | (m) | (m) | $10.24M | (m) | (m) |
| 2025-12-31 | $-13.06M | (m) | (m) | $10.25M | (m) | (m) |
| 2025-09-30 | $-13.50M | (m) | (m) | $10.26M | (m) | (m) |
| 2025-06-30 | $-12.08M | (m) | (m) | $8.93M | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-8.85M | (m) | (m) | $6.41M | (m) | (m) |
| 2024-09-30 | $-8.82M | (m) | (m) | $6.45M | (m) | (m) |
| 2024-06-30 | $-7.31M | (m) | (m) | $4.11M | (m) | (m) |
| 2024-03-31 | $-3.53M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-3.21M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-2.64M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-1.32M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-1.57M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-1.57M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-1.25M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-813.47K | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-393.27K | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-249.15K | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |